ARWR
HealthcareArrowhead Pharmaceuticals, Inc. · Biotechnology · $11B
What is Arrowhead Pharmaceuticals, Inc.?
Arrowhead Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing RNA interference therapies for serious, hard-to-treat diseases. Headquartered in Pasadena, California, it has built one of the broader RNAi pipelines in the sector.
Arrowhead uses RNAi technology to silence specific genes responsible for disease. Its pipeline targets liver disease, cardiovascular conditions, pulmonary disorders, and rare genetic diseases. The company generates revenue primarily through licensing partnerships with larger pharmaceutical companies while advancing its own clinical candidates toward potential approval.
Founded in 1993 and based in Pasadena, California.
- RNAi-based therapeutic pipeline across multiple disease areas
- Liver disease candidates including ARO-AAT and ARO-HSD
- Cardiovascular programs such as ARO-APOC3 and Olpasiran
- Pulmonary and rare disease programs including ARO-ENaC and ARO-DUX4
Is ARWR a Good Stock to Buy?
UQS Score rates ARWR as Good overall, reflecting a balanced profile across its five analytical pillars.
The Quality pillar stands out as Strong, suggesting the company maintains a relatively sound financial foundation for a clinical-stage biotech. The Growth and Risk pillars both register as Good, indicating a pipeline with meaningful upside potential and a manageable risk profile relative to peers.
Valuation is flagged as Elevated, which is worth monitoring given the company has not yet reached commercial-stage revenues at scale.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ARWR pay dividends?
No — Arrowhead Pharmaceuticals, Inc. does not currently pay a dividend.
Arrowhead does not currently pay a dividend. As a clinical-stage company, capital is directed toward advancing its RNAi pipeline through trials and partnership development rather than returning cash to shareholders.
When does ARWR report earnings?
Arrowhead Pharmaceuticals reports earnings on a quarterly cadence, consistent with US-listed equities.
Results tend to reflect milestone payments, partnership revenues, and research spending rather than product sales. Pipeline progress and partnership updates often carry more weight than headline numbers for investors tracking this stage of company.
For the most recent quarter's results, visit Arrowhead Pharmaceuticals' investor relations page directly.
ARWR Price History
-2.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Arrowhead Pharmaceuticals, Inc.?
Based on Arrowhead Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Arrowhead Pharmaceuticals do?
Arrowhead develops RNA interference medicines targeting diseases where few effective treatments exist. Its pipeline spans liver disease, cardiovascular conditions, pulmonary disorders, and rare genetic diseases. The company partners with larger pharmaceutical firms to fund development while advancing its own clinical programs.
Does ARWR pay dividends?
No, Arrowhead does not pay a dividend. The company reinvests available capital into its clinical pipeline and research operations, which is typical for clinical-stage biopharmaceutical companies that have not yet reached broad commercial revenue.
When does ARWR report earnings?
Arrowhead reports on a standard quarterly schedule. Because our data source does not cover specific upcoming dates, check the company's investor relations page for the current earnings calendar.
Is ARWR a good stock to buy?
UQS Score rates ARWR as Good overall. Quality and Risk pillars are among its stronger attributes, while Valuation is flagged as Elevated. Whether it fits your portfolio depends on your risk tolerance and investment horizon. The full pillar breakdown is available to Pro members.
Is ARWR overvalued?
The UQS Valuation pillar for ARWR is rated Elevated, suggesting the market is pricing in meaningful future pipeline success. This is common for clinical-stage biotechs with broad pipelines but limited near-term commercial revenue.
What is ARWR's market cap bracket?
Arrowhead Pharmaceuticals is classified as a mid-cap company, placing it between smaller speculative biotechs and large established pharmaceutical firms in terms of market size.
Is ARWR a long-term quality investment?
From a quality standpoint, ARWR's Strong Quality pillar and Good Risk rating suggest a relatively sound foundation for a clinical-stage biotech. Long-term outcomes will depend heavily on pipeline execution and partnership milestones. Pro members can view the complete UQS analysis.
What sector does ARWR belong to?
Arrowhead Pharmaceuticals operates in the Healthcare sector, specifically within the biopharmaceutical and clinical-stage drug development space, focused on RNA interference technology.
Unlock Full ARWR Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access full financial metrics and quality indicators
- ✓Compare ARWR against sector peers on every pillar
- ✓Track pipeline and valuation signals in one place
Pro Analysis
ARWR — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | 35.7 | 16.7 | 41.0 | 62.5 | 58.8 | 0.0 | -1.5 |
| May 11, 2026 | 37.2 | 16.7 | 41.0 | 62.5 | 68.2 | 0.0 | -18.5 |
| May 5, 2026 | 55.7 | 84.3 | 41.0 | 62.5 | 71.9 | 7.6 | -0.1 |
| May 3, 2026 | 55.8 | 84.4 | 41.0 | 62.5 | 71.9 | 7.7 | 0.0 |
| May 1, 2026 | 55.8 | 84.5 | 41.0 | 62.5 | 71.9 | 7.9 | 0.0 |
| Apr 23, 2026 | 55.8 | 84.5 | 41.0 | 62.5 | 71.9 | 7.8 | -0.2 |
| Apr 22, 2026 | 56.0 | 84.8 | 41.0 | 62.5 | 71.9 | 8.1 | 0.0 |
| Apr 19, 2026 | 56.0 | 84.9 | 41.0 | 62.5 | 71.9 | 8.3 | -0.4 |
| Apr 18, 2026 | 56.4 | 84.9 | 41.0 | 62.5 | 71.9 | 11.0 | -0.6 |
| Apr 17, 2026 | 57.0 | 85.0 | 41.0 | 62.5 | 71.9 | 14.8 | +0.1 |
ARWR — Pillar Breakdown
Quality
— 16.7/100 (25%)Arrowhead Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 62.5/100 (20%)Arrowhead Pharmaceuticals, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 58.8/100 (15%)Arrowhead Pharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Arrowhead Pharmaceuticals, Inc. appears expensively valued relative to its fundamentals and growth prospects.
How many years of FCF the market cap represents.
Moat
— 41/100 (25%)Arrowhead Pharmaceuticals, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ARWR.
Score Composition
Financial Data
More Stock Analysis
How is the ARWR UQS Score Calculated?
The UQS (Unified Quality Score) for Arrowhead Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Arrowhead Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Arrowhead Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.